Autoantibody spark response predicts treatment outcome in patients receiving chemoradiation followed by durvalumab therapy



Summary

A study revealed that the development of new autoantibodies, termed “autoantibody spark,” following chemoradiation therapy (CRT) predicts the effectiveness of subsequent durvalumab immunotherapy in cancer patients. Researchers found that patients exhibiting this “autoantibody spark” – a surge in new autoantibodies after CRT – had significantly better outcomes, including improved progression-free survival and overall survival, compared to those without this response. These findings suggest that the post-CRT autoantibody profile could serve as a valuable biomarker to identify patients most likely to benefit from durvalumab maintenance therapy. The study highlights the complex interplay between CRT and immunotherapy and emphasizes the importance of monitoring autoantibody responses to personalize cancer treatment strategies.

Read more…

Credits: Source

This post is part of “Science/Immunology News”, Follow for more…!!!